Medical Properties Trust Inc. common stock (MPT)

FairStock Score: 74/100 — STEADY

Key Financials

Strengths

• Generates $782 million in annual free cash flow (24.5% yield on market cap)
• Strong Piotroski F-Score of 8/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Revenue growth of 16.6% demonstrates strong top-line momentum
• Attractive 7.0% dividend yield providing steady income returns
• FairStock composite score of 74/100 places it in the top tier across value, quality, and momentum factors

Concerns

• High leverage at 2.13x debt-to-equity increases financial risk and interest expense burden
• Altman Z-Score of -0.1 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Medical Properties Trust Inc. common stock is a small-cap real estate company valued at $3.2 billion. The business generates $1.1 billion in annual revenue with a 1.6% net margin and $782 million in free cash flow. From a quality standpoint, Medical shows near-perfect Piotroski F-Score of 8/9 indicating exceptional financial health and distressed Altman Z-Score of -0.1 warrants caution. On valuation, the stock is solid 5.0% FCF yield. Growth dynamics show revenue growing at 16.6% and profit growth of 104.2%. The 7.0% dividend yield adds an income component for patient holders. Our composite FairStock Score of 74/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Medical's 17% revenue growth trajectory could accelerate as it captures additional market share in the real estate sector. With $782 million in annual free cash flow (24.5% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Elevated leverage at 2.1x D/E means rising interest rates or revenue weakness could strain debt covenants and force asset sales at distressed prices. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer